Valuation
- Market cap
- 531,292,000
- Revenue TTM
- $0
- Net income TTM
- $-90,350,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 401,600
- Avg volume
- 251,926
- Day's range
- $24.86 – $26.95
- Shares out
- 20,011,000
- Stochastic %K
- 8%
- Beta
- 1.71
- Analysts
- Strong Sell
- Price target
- $79.38
Company profile
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license...
Show more
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 855 508 3568
- Website
- https://www.neurogene.com
- Address
- 535 W 24th Street, 5th Floor, New York, United States
Latest news
No headlines yet.
